CFO John Kuch to retire from Xencor

Xencor Inc. (NASDAQ:XNCR), which is developing antibodies and cytokines to treat cancer and autoimmune diseases, said SVP and CFO John Kuch will retire in March 2024. Kuch, who joined Xencor in 2000 as finance director and became SVP and CFO in 2018, will consult for the company once his successor has transitioned into the role. 

Verastem Inc. (NASDAQ:VSTM) hired Mike Crowther as chief commercial and business strategy officer and David Mitchell as SVP, head of regulatory affairs, and promoted Dan Calkins from VP of finance to CFO. Crowther was CBO at Minerva Biotechnologies Corp. and Mitchell was SVP and head of regulatory affairs at Sumitovant Biopharma Inc...